505 related articles for article (PubMed ID: 26699479)
1. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice.
Nishio M; Sugimachi K; Goto H; Wang J; Morikawa T; Miyachi Y; Takano Y; Hikasa H; Itoh T; Suzuki SO; Kurihara H; Aishima S; Leask A; Sasaki T; Nakano T; Nishina H; Nishikawa Y; Sekido Y; Nakao K; Shin-Ya K; Mimori K; Suzuki A
Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E71-80. PubMed ID: 26699479
[TBL] [Abstract][Full Text] [Related]
2. Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice.
Nishio M; Hamada K; Kawahara K; Sasaki M; Noguchi F; Chiba S; Mizuno K; Suzuki SO; Dong Y; Tokuda M; Morikawa T; Hikasa H; Eggenschwiler J; Yabuta N; Nojima H; Nakagawa K; Hata Y; Nishina H; Mimori K; Mori M; Sasaki T; Mak TW; Nakano T; Itami S; Suzuki A
J Clin Invest; 2012 Dec; 122(12):4505-18. PubMed ID: 23143302
[TBL] [Abstract][Full Text] [Related]
3. Altered Expression of Hippo Signaling Pathway Molecules in Intrahepatic Cholangiocarcinoma.
Sugimachi K; Nishio M; Aishima S; Kuroda Y; Iguchi T; Komatsu H; Hirata H; Sakimura S; Eguchi H; Bekki Y; Takenaka K; Maehara Y; Suzuki A; Mimori K
Oncology; 2017; 93(1):67-74. PubMed ID: 28448997
[TBL] [Abstract][Full Text] [Related]
4. MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation.
Otsubo K; Goto H; Nishio M; Kawamura K; Yanagi S; Nishie W; Sasaki T; Maehama T; Nishina H; Mimori K; Nakano T; Shimizu H; Mak TW; Nakao K; Nakanishi Y; Suzuki A
Oncogene; 2017 Jul; 36(29):4201-4211. PubMed ID: 28346423
[TBL] [Abstract][Full Text] [Related]
5. Loss of
Goto H; Nishio M; To Y; Oishi T; Miyachi Y; Maehama T; Nishina H; Akiyama H; Mak TW; Makii Y; Saito T; Yasoda A; Tsumaki N; Suzuki A
Development; 2018 Mar; 145(6):. PubMed ID: 29511023
[TBL] [Abstract][Full Text] [Related]
6. Epithelial Transforming Growth Factor-β Signaling Does Not Contribute to Liver Fibrosis but Protects Mice From Cholangiocarcinoma.
Mu X; Pradere JP; Affò S; Dapito DH; Friedman R; Lefkovitch JH; Schwabe RF
Gastroenterology; 2016 Mar; 150(3):720-33. PubMed ID: 26627606
[TBL] [Abstract][Full Text] [Related]
7. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss.
Morris SM; Baek JY; Koszarek A; Kanngurn S; Knoblaugh SE; Grady WM
Hepatology; 2012 Jan; 55(1):121-31. PubMed ID: 21898503
[TBL] [Abstract][Full Text] [Related]
9. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
[TBL] [Abstract][Full Text] [Related]
10. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
Nagashima S; Bao Y; Hata Y
Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
[TBL] [Abstract][Full Text] [Related]
11. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
13. Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis.
Patel SH; Camargo FD; Yimlamai D
Gastroenterology; 2017 Feb; 152(3):533-545. PubMed ID: 28003097
[TBL] [Abstract][Full Text] [Related]
14. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
[TBL] [Abstract][Full Text] [Related]
15. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ.
Kodaka M; Hata Y
Cell Mol Life Sci; 2015 Jan; 72(2):285-306. PubMed ID: 25266986
[TBL] [Abstract][Full Text] [Related]
16. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
[TBL] [Abstract][Full Text] [Related]
17. Depletion of MOB1A/B causes intestinal epithelial degeneration by suppressing Wnt activity and activating BMP/TGF-β signaling.
Bae JS; Jeon Y; Kim SM; Jang JY; Park MK; Kim IH; Hwang DS; Lim DS; Lee H
Cell Death Dis; 2018 Oct; 9(11):1083. PubMed ID: 30349003
[TBL] [Abstract][Full Text] [Related]
18. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
19. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
[TBL] [Abstract][Full Text] [Related]
20. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
Ko S; Kim M; Molina L; Sirica AE; Monga SP
Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
